company background image
DICE logo

DICE Therapeutics NasdaqGM:DICE Stock Report

Last Price

US$47.55

Market Cap

US$2.3b

7D

0.2%

1Y

131.2%

Updated

10 Aug, 2023

Data

Company Financials +

DICE Therapeutics, Inc.

NasdaqGM:DICE Stock Report

Market Cap: US$2.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

DICE Stock Overview

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas.

DICE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

DICE Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DICE Therapeutics
Historical stock prices
Current Share PriceUS$47.55
52 Week HighUS$47.90
52 Week LowUS$15.08
Beta0
1 Month Change1.67%
3 Month Change32.90%
1 Year Change131.16%
3 Year Changen/a
5 Year Changen/a
Change since IPO28.90%

Recent News & Updates

We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

May 14
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

Recent updates

We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

May 14
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher

Oct 11

Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

Sep 11
Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

DICE Therapeutics GAAP EPS of -$0.58

Aug 11

DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs

Jul 18

Shareholder Returns

DICEUS PharmaceuticalsUS Market
7D0.2%1.2%0.4%
1Y131.2%25.8%28.8%

Return vs Industry: DICE exceeded the US Pharmaceuticals industry which returned 7.3% over the past year.

Return vs Market: DICE exceeded the US Market which returned 4.8% over the past year.

Price Volatility

Is DICE's price volatile compared to industry and market?
DICE volatility
DICE Average Weekly Movement11.3%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: DICE's share price has been volatile over the past 3 months.

Volatility Over Time: DICE's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201381J. Judicehttps://www.dicetherapeutics.com

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company’s lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications.

DICE Therapeutics, Inc. Fundamentals Summary

How do DICE Therapeutics's earnings and revenue compare to its market cap?
DICE fundamental statistics
Market capUS$2.27b
Earnings (TTM)-US$104.24m
Revenue (TTM)n/a

0.0x

P/S Ratio

-21.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DICE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$62.56m
Gross Profit-US$62.56m
Other ExpensesUS$41.68m
Earnings-US$104.24m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.18
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did DICE perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.